比较 Annovis Bio（纽约证券交易所代码：ANVS）和生物技术收购（纳斯达克股票代码：BIOT）

Annovis Bio (NYSE:ANVS – Get Rating) and Biotech Acquisition (NASDAQ:BIOT – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.

Institutional & Insider Ownership

9.0% of Annovis Bio shares are held by institutional investors. Comparatively, 80.0% of Biotech Acquisition shares are held by institutional investors. 39.5% of Annovis Bio shares are held by company insiders. Comparatively, 19.0% of Biotech Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Annovis Bio and Biotech Acquisition's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current recommendations and price targets for Annovis Bio and Biotech Acquisition, as reported by MarketBeat.

Annovis Bio currently has a consensus target price of $40.00, indicating a potential upside of 162.30%. Given Annovis Bio's higher possible upside, analysts plainly believe Annovis Bio is more favorable than Biotech Acquisition.

Risk and Volatility

Annovis Bio has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, Biotech Acquisition has a beta of -0.14, meaning that its stock price is 114% less volatile than the S&P 500.

Profitability

This table compares Annovis Bio and Biotech Acquisition's net margins, return on equity and return on assets.

About Annovis Bio

(Get Rating)

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

About Biotech Acquisition

(Get Rating)

Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.